Pfizer (PFE) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Remains Positive as Pfizer (PFE) Reports a 3Q Beat and raise
October 27, 2015 4:23 PM EDTCowen reiterated an Outperform rating and $43.00 price target on Pfizer (NYSE: PFE) following the company's 3Q earnings results. Q3 sales of $12,087MM (-2%) were $527MM above consensus. EPS of $0.60 (+5%) was $0.09 ahead of consensus. 2015 EPS guidance was raised to $2.16-2.20 from prior $2.04-2.10 range.... More
